Stichting Dutch Covid19 Lidocaine ARDS

Stichting Dutch Covid19 Lidocaine ARDS is a Netherlands-based research foundation established in 2020 to facilitate clinical investigations into the therapeutic potential of lidocaine for severe respiratory conditions. The organization specifically focuses on repurposing intravenous lidocaine to treat Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19. By leveraging the anti-inflammatory and immunomodulatory properties of this well-established small molecule, the foundation aims to reduce the hyperinflammatory response and improve clinical outcomes in critically ill patients. The foundation acts as a sponsor and coordinator for multi-center clinical trials conducted across various Dutch medical institutions. Its primary objective is to determine if systemic lidocaine administration can decrease the duration of mechanical ventilation and lower mortality rates in the intensive care setting.